ArticleCardiovascular and interventional radiology2026
Long-Term Outcomes and Prognostic Factors After Yttrium-90 Resin-Based Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Single-Center Experience.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the long-term efficacy, safety, and prognostic factors associated with transarterial radioembolization with yttrium-90 (Y90-TARE) in unresectable intrahepatic cholangiocarcinoma (ICC). MATERIALS AND
methodsWe retrospectively analyzed 72 patients with unresectable ICC treated with Y90 resin microspheres TARE between 2009 and 2023. Clinical, laboratory, and imaging data were collected. Treatment response was assessed using RECIST 1.1 criteria. Primary outcome measures were overall survival (OS) and progression-free survival (PFS), evaluated through Kaplan-Meier analysis and Cox proportional hazards models. Secondary outcome measures included radiologic response and safety, with adverse events graded according to CIRSE grading system.
resultsTwenty-eight of 72 (38.9%) patients had monofocal tumors, and 45/72 (62.5%) had a tumor burden < 25%. The median index tumor diameter was 6.9 cm (IQR, 3.8-8.2 cm). Median OS and PFS were 17 (95% CI 13.15-20.57) and 7.5 months (95% CI 5.00-9.50), respectively. Target lesion objective response (OR) rate was 40.3%, overall OR was 36.1%. At multivariate analysis, independent predictors of improved OS were lower tumor volume (p = 0.011), TARE as first line (p < 0.001), and selective infusion target (p = 0.012). Monolobar disease (p = 0.010) and selective infusion target (p = 0.029) emerged as independent predictors of longer PFS. TARE as first line (p = 0.062) showed a trend toward significance in multivariable model. TARE was well tolerated, with no major complications observed.
conclusionTARE is a safe and effective treatment for unresectable ICC. Selective infusion, lower tumor load, and administering TARE as first line-with or without concomitant chemotherapy-are independent predictors for prolonged OS and PFS.
Indexed as
Identifiers
41191097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.